Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.

Product Highlight - Zepatier

01 May 2018
ZEPATIER - Elbasvir 50 mg, grazoprevir 100 mg FC tab - Merck Sharp & Dohme
• A fixed-dose combination of a second-generation NS3/4A protease inhibitor and NS5A inhibitor1,2
• ZEPATIER is indicated for the treatment of Chronic Hepatitis C Genotypes 1 and 4 Infection in adults1.
• Powerful CURE* Across Multiple Patient Types1

*Cure of hepatitis C virus (HCV) infection=sustained virologic response, the primary end point in all studies, defined as HCV ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) at 12 weeks after the cessation of treatment (SVR12).1,3

References:
1. Zepatier Package Insert, 10 August 2017.
2. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. 2013;33(suppl 1):80–84.
3. European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.

Further information is available in section 8p, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.